1. Japan Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Takara Bio Inc.

Takara Bio Inc.

TKBIF
Takara Bio Inc.US flagOther OTC
7.30
USD
- -
- -
879.03MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
181.92
203.27
215.66
246.89
243.95
268.34
297.65
287.05
382.73
562.21
648.94
361.56
374.24
202.66
Basic EPS, GAAP
12.93
12.5
8
11.08
11.23
19.39
30.37
31.72
79.28
164.84
132.97
12.3
8.65
3.29
Free Cash Flow per Basic Share
-2.45
-29.44
-11.07
5.37
17.17
19.46
-2.48
18.99
42.34
-46.12
257.57
-92.76
-36.84
-15.1
Dividend per Share
0.98
1.05
1.19
1.49
1.79
3.99
4.49
6.98
7.99
15.97
32.95
41.99
17.02
0.04
Book Value per Share
134.18
189.16
191.89
201.47
210.91
226.3
252.18
277.92
349.21
498.06
598.03
568.76
560.3
555.92
Tangible Book Value per Share
347.92
463.75
470.4
476.78
479.03
396.9
427.4
458.7
539.19
721.7
858.74
862.29
896.37
894.05
Basic Weighted Avg Shares
113
118
120
120
120
120
120
120
120
120
120
120
120
120
Sales/Revenue/Turnover
20,564
23,905
25,969
29,729
29,375
32,312
35,841
34,565
46,086
67,699
78,142
43,505
45,039
24,389
Operating Margin (%)
8.25
8.19
8.88
8.98
10.91
11.01
15.25
18.16
30.28
42.69
26.29
6.9
5.03
6.53
Depreciation Expense
1,511
1,467
1,672
2,067
2,049
3,217
3,375
3,530
3,786
4,149
4,735
5,021
4,481
2,532
Net Income, GAAP
1,462
1,470
963
1,334
1,352
2,335
3,657
3,819
9,547
19,849
16,012
1,480
1,041
396
Effective Tax Rate (%)
35.67
33.23
61.31
53.87
51.66
30.44
23.82
29.47
29.3
27.69
24.39
47.07
45.57
67.51
Profit Margin (%)
7.11
6.15
3.71
4.49
4.6
7.23
10.2
11.05
20.72
29.32
20.49
3.4
2.31
1.62
Working Capital
27,161
37,445
31,008
36,728
37,939
28,771
29,258
32,139
35,924
50,761
63,194
55,591
50,548
57,063
LT Debt
273
225
178
130
82
- -
- -
986
1,003
910
821
788
908
- -
Total Equity
41,463
57,124
59,640
60,107
59,983
61,956
64,093
66,589
74,300
96,062
112,452
111,782
115,846
116,153
Return on Invested Capital (%)
2.7
2.62
1.51
2.04
2.55
4.03
6.56
6.66
13.42
23.07
14.34
1.4
1.07
0.45
Return on Capital (%)
9.91
7.77
4.21
5.54
5.38
8.85
12.6
11.71
24.44
37.9
23.8
2.05
1.45
0.57
Return on Common Equity (%)
10.15
7.86
4.25
5.63
5.45
8.87
12.69
11.97
25.28
38.91
24.26
2.11
1.53
0.59

Capital Structure

FRC

•

in mil. unless spec.
Mar'24
Jun'25
Sep'25
ST Debt
180
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
788
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
120
- -
120
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Mar'24
Jun'25
Sep'25
Total Current Assets
62,759
- -
63,771
Cash, Cash Equivalents & STI
35,416
- -
39,957
Accounts Receivable, Net
10,214
- -
9,230
Inventories
11,850
- -
12,798
Total Current Liabilities
7,168
- -
6,708
Payables & Accruals
- -
- -
- -
ST Debt
180
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
7.22%
12.19%
3.64%
Free Cash Flow
-183.41%
-188.14%
-60.27%
Net Income, GAAP
29.18%
23.63%
-29.66%
Sales/Revenue/Turnover
8.55%
10.97%
3.53%
Total Cash Common Dividend
42.47%
37.7%
-59.46%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
9,176
9,940
10,618
13,771
43,505
2025
- -
- -
- -
- -
45,039
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2.65
- -
- -
- -
12.3
2025
- -
- -
- -
- -
8.65
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
40.46
- -
- -
- -
41.99
2025
- -
- -
- -
- -
17.02
2026
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Tsuyoshi Miyamura
Full Time Employees
1,838
Sector
Healthcare
Industry
Biotechnology
Address
7-4-38 Nojihigashi Kusatsu SH Japan 525-0058
IPO Date
Apr 27, 2020
Website
takara-bio.com
Similar Companies
Akari Therapeutics, Plc (AKTX)
AnnJi (7754.TWO)
Anew Medical, Inc. (WENA)
Fresh2 Group Limited (FRES)
Tevogen Bio Holdings Inc. (TVGN)
Hangzhou Tigermed Consulting Co., Ltd (3347.HK)
Business
Takara Bio Inc. (TKBIF) develops, manufactures and markets reagents, scientific instruments, contract development and manufacturing organization (CDMO) services and gene therapies for life science research, drug discovery and regenerative medicine. The company offers research reagents including PCR kits, reverse transcriptases, polymerases, ligation kits, RNA cleanup and DNA purification products, competent cells, NGS library construction kits and immune profiling tools under brands such as Takara, Clontech and Cellartis; scientific instruments for qPCR, cell automation and genetic analysis; CDMO services for viral and plasmid vectors, gene and cell therapy products, quality and safety testing; and proprietary gene therapies like NY-ESO-1 siTCR for cancer, SonuAAV for inner ear delivery and CAR-T technologies including CD19 JAK/STAT and siTCR platforms. Takara Bio operates globally with manufacturing and sales in Japan, the United States, China, Europe, India and other Asian regions, targeting academic institutions, corporate researchers, clinical laboratories and pharmaceutical companies. Founded in 2002 as a spin-off from Takara Shuzo Co. Ltd. (established 1925) and headquartered in Kusatsu, Shiga, Japan, the company maintains subsidiaries including Takara Bio USA Inc. in San Jose, California; Takara Bio Europe; Takara Biotechnology (Dalian) Co. Ltd.; and Takara Bio India. Recent developments include the January 2025 acquisitions of Curio Bioscience Inc. to enhance spatial genomics and single-cell omics capabilities and ViSpot Inc. to expand its subsidiary portfolio; a June 2024 business partnership with Gap Junction Therapeutics for AAV gene therapy targeting hereditary hearing loss; completion of clinical trial notification in September 2025 for confirmatory studies of NY-ESO-1 siTCR gene therapy in Japan; announcement of the Takara Bio Group Long-Term Vision 2050 in September 2025; redesign of regulatory strategy for NY-ESO-1 siTCR in Japan in June 2025; and revisions to financial results forecasts in November 2025 reflecting no dividends and partial executive remuneration return.